This is underscored by the results of a clinical trial comparing the development of obese adults who received either semaglutide or liraglutide in addition to nutritional advice and physical activity, and significantly greater weight loss was achieved in the semaglutide group [102]
When you choose Centra Internal Medicine and Dr
See Conducting Remote Regulatory Assessments: Questions and Answers, Guidance for Industry (June 2025)
Metabolic indicators that may be associated with reduced GLP-1 activity include: Persistent elevated blood glucose levels , particularly postprandial (after-meal) hyperglycaemia Difficulty achieving or maintaining a healthy weight despite dietary efforts Increased appetite and reduced satiety after meals, leading to frequent snacking Diagnosis of type 2 diabetes or non-diabetic hyperglycaemia (NDH, sometimes called prediabetes), conditions where GLP-1 response is often blunted Features of metabolic syndrome , including central obesity, hypertension, and dyslipidaemia Individuals may also notice practical symptoms such as feeling hungry shortly after eating substantial meals, experiencing energy crashes following carbohydrate-rich foods, or finding portion control particularly challenging
